Trin canser y brostad datblygedig lleol
Dyma ein hymchwilwyr yn datgelu'r technegau gorau am drin canser y brostad datblygedig lleol.
Mae'r cynnwys isod ar gael yn Saesneg yn unig.
Locally advanced prostate cancer affects 20,000 men per year in the US, and 4,000 men per year in the UK. Before embarking on this new research, there was no consensus on the standard of care or the best way to treat the condition.
Finding the best treatment
Previous studies in patients compared hormone therapy alone, radiotherapy alone, and hormone therapy plus radiotherapy. However, these trials failed to sufficient patients to show any differences in outcomes, and the result was uncertainty about the role of radiotherapy in such patients.
An international randomised clinical trial led by Cardiff researchers sought to end the confusion by identifying whether combining hormone therapy plus radiotherapy improves the outcome for sufferers. The trial showed that treating locally advanced disease with a combination of radiotherapy and hormone therapy halved the risks of dying of prostate cancer.
Life saving reserach
Our research has proven that combining radiotherapy and hormone therapy halves the risks of dying of prostate cancer.
Changing treatment worldwide
It is now a standard of care, enshrined in European and North American guidelines, that all such patients who are fit enough to receive it, should now be offered combined modality radiotherapy plus hormone therapy.
Professor, Institute of Cancer & Genetics
Detholiad o gyhoeddiadau
- Warde, P. et al., 2011. Combined androgen deprivation therapy and radiation therapy for locally advanced prostate cancer: A randomised, phase 3 trial. The Lancet 378 (9809), pp.2104-2111. (10.1016/S0140-6736(11)61095-7)
- Enache, D. I. et al. 2006. Solvent-Free Oxidation of Primary Alcohols to Aldehydes Using Au-Pd/TiO2 Catalysts. Science 311 (5759), pp.362-365. (10.1126/science.1120560)
- Mason, M. D. et al. 2000. Randomized trials in early prostate cancer. II: Hormone therapy and radiotherapy for locally advanced disease: A question is still unanswered. Clinical Oncology 12 (4), pp.215-216. (10.1053/clon.2000.9156)
This research was made possible through our close partnership with and support from: